Amanda C. Guidon

Amanda C. Guidon

Auto-generated profile, based on publicly available information

Amanda C. Guidon

Department of Neurology Massachusetts General Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AGAmanda C Guidon
Amanda C Guidon
LBLeeann B Burton
Leeann B Burton
BCBart K Chwalisz
Bart K Chwalisz
JHJames Hillis
James Hillis
TSTeilo H Schaller
Teilo H Schaller
KRKerry Reynolds
Kerry Reynolds
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.

2 June 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
AGAmanda C. Guidon
Amanda C. Guidon
AAAnthony A. Amato
Anthony A. Amato
The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.

22 February 2020 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
DDDivyanshu Dubey
Divyanshu Dubey
WDWilliam S. David
William S. David
KRKerry L. Reynolds
Kerry L. Reynolds
DCDonald F. Chute
Donald F. Chute
NCNathan F. Clement
Nathan F. Clement
AGAmanda C. Guidon
Amanda C. Guidon

22 May 2020 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
PAPria Anand
Pria Anand
MSMichaël C. C. Slama
Michaël C. C. Slama
MKMichelle Kaku
Michelle Kaku
COCharlene Ong
Charlene Ong
ACAnna M. Cervantes‐Arslanian
Anna M. Cervantes‐Arslanian
AGAmanda C. Guidon
Amanda C. Guidon

7 July 2021 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
AGAmanda C. Guidon
Amanda C. Guidon
SMSrikanth Muppidi
Srikanth Muppidi
RNRichard J. Nowak
Richard J. Nowak
JGJeffrey T. Guptill
Jeffrey T. Guptill
MHMichael K. Hehir
Michael K. Hehir
JHJames F. Howard
James F. Howard

2 July 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
KRKerry Reynolds
Kerry Reynolds
SAShaily Arora
Shaily Arora
RERavikumar Komandur Elayavilli
Ravikumar Komandur Elayavilli
WLWilliam C Louv
William C Louv
TSTeilo H Schaller
Teilo H Schaller
ESElad Sharon
Elad Sharon
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk–benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs.